First human trial launches for experimental drug BY002
NCT ID NCT07640438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is the first time BY002 is being tested in humans. It aims to check the drug's safety and how the body processes it. Healthy adults will receive either BY002 or a placebo by injection. Researchers will monitor for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BY002
What this could lead to
If safe, this could pave the way for future studies testing BY002 as a treatment for certain conditions.
What could go wrong
This is an early Phase 1 trial in healthy people, so it cannot show whether BY002 works for any disease. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 31003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••